flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 FLOW- the Visual Abstract — NephJC flow trial semaglutide kidney outcomes
Description
Ongoing Medical Supervision and Dose Optimization MEDVi's model emphasizes that GLP-1 therapy requires sustained medical oversight, not simply initial prescription followed by patient self-management
The following week, a small gain appears on the scale
Eat slowly and stop at comfortable, not full. Because the stomach empties more slowly, eating fast can lead to discomfort or nausea
Every protein habit and walking session counts
Fits the context
